We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Stem Cells Used to Grow Human Heart Valves

By HospiMedica staff writers
Posted on 20 Dec 2006
A new study reports that human heart valves have been grown for the first time by using stem cells found in amniotic fluid. More...


Researchers from the University of Zurich (Switzerland) harvested autologous fetal stem cells from the womb during amniocentesis and seeded them onto three-dimensional (3D) matrices--shaped like a small ink pen and made of biodegradable plastic--followed by biomimetic in-vitro conditioning that enabled the development of the neo-heart valve tissue. Four to six weeks were needed to grow each of the 12 valves created in the experiment. Tests showed the valves appeared to function normally.

The idea behind the research is to create new valves in the laboratory while the pregnancy progresses, and have them ready to implant in a baby with heart defects after it is born. Amniotic fluid is a rich source of stem cells and also could be frozen for years, the researchers said, and could therefore potentially be used to create replacement parts for aging or diseased valves in adults as well. Also, by using cells the fetus sheds in amniotic fluid, this procedure avoids controversy because it does not involve destroying embryos to obtain stem cells. The research results were presented at the American Heart Association (AHA) Scientific Sessions, held in Chicago (IL, USA) in November 2006.

"We have demonstrated that, based on a cell source which you can obtain prenatally, you can fabricate a living heart valve from these cells which may be ready to use at the time of birth. If you have to wait for the baby to arrive to collect cells, it takes another six to eight weeks before a valve is ready to implant, which is often too late,” said lead author Dr. Simon Hoerstrup, director of cardiovascular research and the division of regenerative medicine. "This may open a whole new therapy concept to the treatment of congenital heart defects.”

Since it is possible to diagnose heart malformation or heart-valve defects in the 20th week of pregnancy with the help of ultrasound tests, replacement hearts grown out of stem cells can be easily used to treat babies born with such defects, added Dr. Hoerstrup.



Related Links:
University of Zurich

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.